PT - JOURNAL ARTICLE AU - Sendor, Rachel AU - Banek, Kristin AU - Kashamuka, Melchior Mwandagalirwa AU - Mvuama, Nono AU - Bala, Joseph A. AU - Nkalani, Marthe AU - Kihuma, Georges AU - Atibu, Joseph AU - Thwai, Kyaw L. AU - Svec, W. Matthew AU - Goel, Varun AU - Nseka, Tommy AU - Lin, Jessica T. AU - Bailey, Jeffrey A. AU - Emch, Michael AU - Carrel, Margaret AU - Juliano, Jonathan J. AU - Tshefu, Antoinette AU - Parr, Jonathan B. TI - Epidemiology of <em>Plasmodium malariae</em> and <em>Plasmodium ovale</em> spp. in a highly malaria-endemic country: a longitudinal cohort study in Kinshasa Province, Democratic Republic of Congo AID - 10.1101/2023.04.20.23288826 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.20.23288826 4099 - http://medrxiv.org/content/early/2023/04/25/2023.04.20.23288826.short 4100 - http://medrxiv.org/content/early/2023/04/25/2023.04.20.23288826.full AB - Background Increasing reports suggest that non-falciparum species are an underappreciated cause of malaria in sub-Saharan Africa, but their epidemiology is not well-defined. This is particularly true in regions of high P. falciparum endemicity such as the Democratic Republic of Congo (DRC), where 12% of the world’s malaria cases and 13% of deaths occur.Methods and Findings The cumulative incidence and prevalence of P. malariae and P. ovale spp. infection detected by real-time PCR were estimated among children and adults within a longitudinal study conducted in seven rural, peri-urban, and urban sites from 2015-2017 in Kinshasa Province, DRC. Participants were sampled at biannual household survey visits (asymptomatic) and during routine health facility visits (symptomatic). Participant-level characteristics associated with non-falciparum infections were estimated for single- and mixed-species infections. Among 9,089 samples collected from 1,565 participants over a 3-year period, the incidence of P. malariae and P. ovale spp. infection was 11% (95% CI: 9%-12%) and 7% (95% CI: 5%-8%) by one year, respectively, compared to a 67% (95% CI: 64%-70%) one-year cumulative incidence of P. falciparum infection. Incidence continued to rise in the second year of follow-up, reaching 26% and 15% in school-age children (5-14yo) for P. malariae and P. ovale spp., respectively. Prevalence of P. malariae, P. ovale spp., and P. falciparum infections during household visits were 3% (95% CI: 3%-4%), 1% (95% CI: 1%-2%), and 35% (95% CI: 33%-36%), respectively. Non-falciparum malaria was more prevalent in rural and peri-urban vs. urban sites, in school-age children, and among those with P. falciparum co-infection. A crude association was detected between P. malariae and any anemia in the symptomatic clinic population, although this association did not hold when stratified by anemia severity. No crude associations were detected between non-falciparum infection and fever prevalence.Conclusions P. falciparum remains the primary driver of malaria morbidity and mortality in the DRC. However, non-falciparum species also pose an infection risk across sites of varying urbanicity and malaria endemicity within Kinshasa, DRC, particularly among children under 15 years of age. As P. falciparum interventions gain traction in high-burden settings like the DRC, continued surveillance and improved understanding of non-falciparum infections are warranted.Competing Interest StatementRS was previously employed by IQVIA and employment had concluded prior to any support on this research study; JBP reports research support from Gilead Sciences, non-financial support from Abbott Laboratories, and consulting for Zymeron Corporation, all outside the scope of this study.Funding StatementThis study was funded in part by the National Institutes of Health (NIH) [R21 AI148579 to JBP and JTL; R01 AI139520 to JAB; R01AI132547 and K24AI134990 to JJJ; R01AI107949 and R01AI129812 to AT; T32AI070114 to RS and KB], and by an ASTMH/Burroughs-Wellcome Fund award to JBP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Boards at the University of North Carolina at Chapel Hill (IRB#: 14-0489) the University of Iowa (#201701201), and the Kinshasa School of Public Health (ESP/CE/015/014).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made publicly available through the Carolina Digital Repository.